Vertex Pharmaceuticals (VRTX) Non-Current Deferred Tax Liability (2009 - 2018)

Vertex Pharmaceuticals' Non-Current Deferred Tax Liability history runs 10 years deep, the most recent figure standing at $9.4 million for Q3 2018.

• In Q3 2018, Non-Current Deferred Tax Liability fell 11.87% year-over-year to $9.4 million; the TTM figure through Sep 2018 stood at $9.4 million (down 11.87% YoY), while the FY2017 annual figure was $5.5 million, down 95.87% from the prior year.
• Non-Current Deferred Tax Liability was $9.4 million for Q3 2018 at Vertex Pharmaceuticals, up from $9.3 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $136.6 million in Q2 2017 to a low of $5.5 million in Q4 2017.
• Historically, Non-Current Deferred Tax Liability has averaged $74.5 million across 5 years, with a median of $111.2 million in 2015.
• The sharpest annual moves came in 2015 and 2017: Non-Current Deferred Tax Liability jumped 853.6% in 2015, then tumbled 95.87% in 2017.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $11.5 million in 2014, then surged by 853.6% to $110.1 million in 2015, then advanced by 21.48% to $133.7 million in 2016, then sank by 95.87% to $5.5 million in 2017, then soared by 70.61% to $9.4 million in 2018.
• The last three Non-Current Deferred Tax Liability figures came in at $9.4 million (Q3 2018), $9.3 million (Q2 2018), and $9.6 million (Q1 2018), per Business Quant data.